z-logo
Premium
γδT‐cell function in sepsis is modulated by C5a receptor signalling
Author(s) -
Han Gencheng,
Geng Shaoxia,
Li Yurong,
Chen Guojiang,
Wang Renxi,
Li Xinying,
Ma Yuanfang,
Shen Beifen,
Li Yan
Publication year - 2011
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/j.1365-2567.2011.03445.x
Subject(s) - microbiology and biotechnology , c5a receptor , biology , pi3k/akt/mtor pathway , signal transduction , complement system , immunology , immune system
Summary We previously showed that γδT cells are involved in the pathogenesis of sepsis, but, the underlying mechanisms remained unclear. The present study demonstrates, for the first time, that γδT cells express the complement C5a receptor (C5aR, CD88) and that CD88 expression in γδT cells was up‐regulated in mice following sepsis both at protein and mRNA levels. Complement C5a itself contributed to the regulation of C5aR expression on γδT cells, as (i) neutralization of C5a in vivo prevented the expression of C5aR on γδT cells in septic mice and (ii) incubation of mouse spleen cells or purified γδT cells with recombinant C5a in vitro increased CD88 expression by γδT cells at both protein and mRNA levels. C5a receptor on γδT cells also mediates increased interleukin‐17 (IL‐17) expression as incubation of mouse spleen cells or purified γδT cells with recombinant C5a promotes the IL‐17 expression by γδT cells. Ligation of the C5aR on γδT cells activated the phosphoinositide 3‐kinase (PI3K)/Akt signalling pathway, which enhances CD88 expression and promotes IL‐17 secretion. These results demonstrate that C5a acts directly on the C5aR expressed on γδT cells, resulting in cell activation, and subsequently enhances their capacity for IL‐17 production. The up‐regulation of the PI3K/Akt pathway following C5a stimulation contributes to up‐regulation of γδT‐cell function.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here